Multiple sources are pointing to a new report that Merck paid Elsevier, a leading publisher, to produce several volumes of the Australasian Journal of Bone and Joint Medicine, which appeared to be a peer-reviewed journal, but was really little more than marketing material for the pharmaceutical company.
Merck and Elsevier Published Fake Journal
May 4, 2009
Share this post
2 Comments

Law Bytes
Episode 268: Sara Grimes on the Moral Panic Behind Banning Kids from Social Media and AI Chatbots
byMichael Geist

May 11, 2026
Michael Geist
May 4, 2026
Michael Geist
April 27, 2026
Michael Geist
Ep. 265 – Jason Millar on Claude Mythos, Project Glasswing, and the Governance Crisis in Frontier AI
April 20, 2026
Michael Geist
Search Results placeholder
Michael Geist on Substack
Recent Posts
The Lawful Access Two-Headed Surveillance Monster: How Bill C-22 Went Off the Rails
How Much Further Will Lawful Access Go?: Police Chief Tells Bill C-22 Hearing That Three Years of Metadata Retention Would Be “Ideal”
Bill C-22’s Groundhog Day: Why the Government’s Dismissal of Signal, Apple and the U.S. Congress Concerns Runs Back the Disastrous Online News Act Playbook
Slick Videos Won’t Save Lawful Access: Why The Government’s Bill C-22 Defence Avoids the Charter, Privacy and Security Concerns Raised By Critics
The Law Bytes Podcast, Episode 268: Sara Grimes on the Moral Panic Behind Banning Kids from Social Media and AI Chatbots

And educational institutions subscribe to Elsevier ScienceDirect
1. Publish a fake journal with Elsevier and the like
2. Make educational institurions subscribe to Elsevier and the like
3. Tie university professors with Big Pharma
4. PROFIT!
Regarding [3], visit http://www.ahrp.org/cms/content/view/523/9/
Harvard Medical Students Rebel Against Big Pharma
“The students say they worry that pharmaceutical industry scandals in recent years – including some criminal convictions, billions of dollars in fines, proof of bias in research and publishing and false marketing claims – have cast a bad light on the medical profession. And they criticize Harvard as being less vigilant than other leading medical schools in monitoring potential financial conflicts by faculty members.”
Marketing material, yes, but…
The info that the publication was paid for by Merck could be inferred, if you took the time. In the item pointed to, the ONLY advertisements were from Merck (at least that was the only ones that I noticed).
However, I’d agree that it should have been specifically mentioned. Sort of like the “Medi-Facts” commercials airing these days.